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There is accumulating evidence that the intestinal barrier and the microbiota may play a role in the systemic inflammation present
in HD patients. HD patients are subject to a number of unique factors, some related to the HD process and others simply to the
uraemic milieu but with common characteristic that they can both alter the intestinal barrier and the microbiota. This review is
intended to provide an overview of the current methods for measuring such changes in HD patients, the mechanisms behind these
changes, and potential strategies that may mitigate these modifications. Lastly, intradialytic exercise is an increasingly employed
intervention inHDpatients; however the potential implications that thismay have for the intestinal barrier are not known; therefore
future research directions are also covered.
1. Introduction
Cardiovascular disease is the leading cause of mortality
in patients with end stage renal disease (ESRD) receiving
haemodialysis (HD). Chronic systemic inflammation is a
nontraditional cardiovascular risk factor that is present and
perpetual in HD patients and is associated with increased
morbidity and mortality [1]. Other clinical features and con-
sequences of inflammation in HD patients include frailty,
impaired physical functioning, and anaemia as well as an
increased risk of hospitalisation and death [2]. Several in-
terrelated factors are all believed to add to the chronic
systemic inflammatory environment seen in HD patients.
These include (but are not limited to) uraemic toxins,
hypervolaemia, hypertension, increased amounts of reactive
oxygen species (ROS), reductions in antioxidant defence,
compromised protein energy state, increased adipose tissue,
infection (including vascular access related, bacterial, and
viral infection), and comorbid conditions such as diabetes [1–
3].
The gastrointestinal tract is another source of inflamma-
tion in HD patients, which is starting to receive increasing
interest [4–6]. Significant disruptions to the intestinal barrier
are thought to take place in HD patients catalysed by the
uraemic environment and importantly the process of HD
itself [6–8]. Other factors which are unique to this popula-
tion, such as changes to the composition of diet and medi-
cation, are also thought to contribute [6]. It is thought that
such disruptions result in the translocation of endotoxins,
digestive enzymes, and gut-produced toxic metabolites into
the central circulation [6, 8–10].
These observations were initially based on data reporting
the presence of inflammation throughout the gastrointestinal
tract (including esophagitis, gastritis, duodenitis, enteritis,
and colitis) in a postmortem study of 78 prevalent HD
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Figure 1: The intestinal barrier.
patients [11]. Subsequent studies have shown elevated levels of
circulating (gut-derived) endotoxin inHDpatients compared
to control patients [8, 12, 13], with the highest levels being
reported in HD and continuous ambulatory peritoneal dialy-
sis (PD) patients [8, 14], when compared to chronic kidney
disease (CKD) patients (stages 3 to 5) [8] and transplant
patients [12]. Levels of endotoxin in HD patients have been
associated with increased levels of systemic inflammation, as
well as increased cardiovascular events and mortality [9, 15,
16].
2. The Intestinal Barrier
The intestinal barrier has two primary functions, the first of
which is to prevent the transport of harmful substances such
as endotoxins, gut-produced antigens, and digestive enzymes
from the lumen to the internal environment [17].
Secondly, it acts as a semipermeable barrier to allow the
selective translocation of essential dietary nutrients, elec-
trolytes, and water from the intestinal lumen into the circula-
tion [17]. This physical intestinal barrier comprises a contin-
uous layer of epithelial cells sealed by intercellular junctional
complexes (termed tight junctions [TJs]). These TJs are
located on the apical end of the lateral surface of the epithelial
cells (Figure 1) [18].The epithelial stem cells differentiate into
four classes of epithelial cells which originate in the crypt
and then migrate upwards along the villus axis [19]. The
absorptive enterocyte cells comprise 80% of small intestinal
epithelial cells, while the goblet cells, the enteroendocrine
cells, and the Paneth cells make up the remainder [19]. The
Paneth cells are located in the intestinal crypt; their function
includes secretion of antimicrobial peptides (e.g., lysozyme
and cryptdins or defensins) into the villous crypt, and these
are retained in the mucus layer enabling their bactericidal
activity to be concentrated near the epithelium [19]. The
goblet cells secrete trefoil peptides and mucus which is
formed from both glycoproteins and water [20]. This layer
of mucus overlays the intestinal epithelium and has an
important function in maintaining the intestinal barrier [20,
21].
The TJs are the paracellular barrier and are formed by
transmembrane sealing proteins, which include members
of the claudin family, occludin, and junctional adhesion
molecules. These sealing proteins (claudin and occludin)
interact with cytoplasmic proteins including zonula occlu-
dens proteins (ZO-1, ZO-2, and ZO-3), from the adjacent cell,
and are linked to the cytoskeleton (Figure 1). Claudin and
occludin formation at the TJ are regulated by various sig-
nalling pathways, which results in the phosphorylation of
phosphates, kinases, and signalling molecules [22].
The transcellular barrier is controlled by the enterocyte
cells only allowing the permeation of solutes predominantly
regulated by specific transporters for amino acids, elec-
trolytes, short-chain fatty acids, and sugars [23]. The TJs
function as a selective semipermeable barrier that allows the
passage of ions and solutes through the paracellular space
while prohibiting the translocation of endotoxin, microbial
fragments, and gut-produced toxins into the circulation [17].
3. Consequences of Changes in Intestinal
Barrier Status in Haemodialysis Patients
The intestines contain large amounts of Gram-negative bac-
teria [34], which contain complex lipopolysaccharides (LPS)
termed endotoxin within the outer cell wall [34, 35]. The
terms LPS and endotoxin are frequently used interchange-
ably. Endotoxin is the natural form of LPS which occurs
within the outer wall of Gram-negative bacteria, while LPS
refers to the purified form which is used as measurement
standard in endotoxin detection assays [36]. Endotoxins have
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a molecular weight varying from 10 to a 1000 kDa and are
comprised of a lipidA antigen attached to a carbohydrate core
and polysaccharide O antigen [37].
It is normal for small amounts of endotoxins to cross the
intestinal barrier into the circulation; they are regulated and
removed by reticuloendothelial cells, phagocytes in the liver
[38],mesenteric lymphnodes [39], anti-endotoxin antibodies
[38, 40, 41], and lipoproteins [42].This low level of endotoxin
crossing the intestinal barrier allows an interaction between
the luminal contents and the mucosal immune system, thus
preventing an excessive immune response when an antigen
is delivered from the gut into the portal circulation; this
allows a state of antigen specific tolerance known as oral
tolerance [40]. These bacterial components are harmless
when they are restricted to the gut [41] but are highly toxic
if they cross the intestinal barrier and enter the circulation
[38]. The translocation of endotoxin across the intestinal
barrier either through the transcellular or paracellular route
induces inflammation through its attachment to toll-like
receptor-4 (TLR-4), and cluster of differentiation-14 (CD-
14) receptors expressed on the surface of human monocytes
and macrophages. This process triggers the release of proin-
flammatory cytokines such as tumour necrosis factor-alpha
(TNF-𝛼), interferon-𝛼 (IFN-𝛼), and interleukin-6 (IL-6), via
the transcriptional nuclear factor k-light chain enhancer of
activated B cells (NF-𝜅b) [43], which results in an inflam-
matory environment. The influx of these proinflammatory
cytokines can further exacerbate the translocation of endo-
toxin through disruption in the transcellular tight junction
proteins (claudin and occludin) promoting systemic inflam-
mation [44, 45]. Not only are disturbances to the intestinal
barrier a source of inflammation in HD patients through
the process of endotoxin translocation, but they also may
contribute to the high number of infections reported in this
patient population [46]. The translocation of endotoxins and
luminal toxins could place additional stress on the immune
system of HD patients and therefore could be less able to
defend against other potential pathogens [47].These theories
are yet to be confirmed however.
Increased circulatory concentration of endotoxin is a
strong risk factor for the development of atherosclerosis in
the general population [48] and may be related to the degree
of both atherosclerosis and inflammation in PD patients [14].
This suggests that the translocation of endotoxin and the
consequential development of atherosclerosis may be one
element responsible for the increased cardiovascular risk in
HD patients. Furthermore, changes to the intestinal barrier,
the translocation of endotoxin, and diffusion of urea into
the intestinal lumen may also increase the circulating levels
of toxic metabolites such as 𝑝-cresyl sulphate (PC) and
indoxyl sulphate (IS), which are independent predictors of
cardiovascular disease and mortality [49–52]. Intriguingly,
PC and IS have also been shown to be predictors of CKD
progression [53].
4. Haemodialysis Related Factors
4.1. The Haemodialysis Process. Levels of circulating endo-
toxin are significantly elevated in the circulation of HD
patients compared to healthy controls [8, 12, 13] (Table 1).
Studies also suggest that initiation of HD results in a signifi-
cant increase in endotoxin levels (from 0.13 ± 0.3EU/mL to
0.34 ± 0.42EU/mL) [8]. This is supported by Terawaki et al.
[33], who observed increased concentrations of circulatory
endotoxin in patients at the end of HD compared to the
beginning, though differences did not reach statistical signif-
icance [33]. Conversely, Markum et al. [27] found no change
in endotoxin levels before and immediately following HD,
although this may be explained by a small sample size and
the timing of samples. It is known that HD in combination
with ultrafiltration results in a systemic haemodynamic per-
turbation with significant splanchnic ischaemia and hypoxia
[7, 8, 54].This effect is accentuated in patients who have large
ultrafiltration volumes during HD [26]. This in turn results
in disturbances to the intestinal barrier and significant rises
in circulating endotoxin [8, 26]. The vascular architecture
of the intestines makes them particularly sensitive to low
oxygen environments (both ischaemia and hypoxia) [55],
for example, when blood flow is shunted away from the
splanchnic region during HD. Intriguingly, it is known that
body temperature increases during HD [56] and, given that
rises in core temperature have been shown to disturb the
intestinal barrier [57–59], it is likely that this increase in blood
temperature during HD may have direct implications for the
translocation of endotoxin.
4.2. Haemodialysis Frequency, Ultrafiltration, and Dialysate.
A cross-sectional study showed thrice weekly (conventional)
HD was associated with a significantly higher circulating
endotoxin level compared to both nocturnal and short daily
HD [26] (Table 1). This may be explained by the lower
ultrafiltration volumes and rates in the nonconventional HD
groups, resulting in lower splanchnic ischaemia and hypoxia
and less disturbance to the intestinal barrier [26]. This study
concluded that less aggressive ultrafiltration may be a useful
strategy to reduce intestinal barrier disturbances in HD
patients.These observationsmay be explained by the findings
of another study [60], which postulated that smaller intradi-
alytic fluid gains and the resultant decrease in gut oedema
result in reduced endotoxin translocation. Gut oedema has
been shown to perturb the intestinal barrier and increase
circulating endotoxin levels in chronic heart failure patients
[61].
It has previously been shown that cooling the dialysate
during treatment has a protective effect on vulnerable vas-
cular beds such as the heart [62, 63] and the brain [64].
This is believed to be driven by an improvement in systemic
vascular resistance [62]. It is therefore entirely possible that
cooled dialysate can have a protective effect on the intestine.
As previously mentioned, body temperature increases during
HD [56]; cooled dialysate may protect the intestine not only
through haemodynamic mechanisms but also through the
direct effect of lower temperature which may itself abrogate
any HD induced changes to the intestinal barrier [58].
There is an increasing interest in how changes to the
microbiota in HD patients result in the production of toxic
metabolites such as PC and IS [5, 6]. By modifying either the
dialysis frequency or ultrafiltration (or both) to induce lower
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Table 1: Studies reporting circulating endotoxin in HD patients.
Study Patients(𝑛)
Detection
method
HD patients endotoxin
concentrations (reported as mean ±
SD or median-range)
Control group endotoxin
concentrations
Timing of Blood Samples
(before, during, or after
HD)
[15] 50 LAL assay (gelclot) 76.30 ± 42.09 pg/mL N/A After HD
[9] 306 LAL assay(chromogenic) 2.31 ± 3.10 EU/mL N/A Not reported
[24] 50 LAL assay(chromogenic) 0.69 ± 0.30 EU/mL
0.04 ± 0.01 EU/ml (n = 15)
[25]. Before HD and after HD
[16] 25 LAL assay(chromogenic)
0.302 ± 0.083 EU/mL and 0.209 ±
0.044 EU/mL (before and after 4
weeks of conversion to ultrapure
dialysate)
N/A Not reported
[26] 86 LAL assay(chromogenic)
0.66 ± 0.29 EU/mL and 0.08 ±
0.04 EU/mL (for conventional and
nocturnal HD patients)
N/A Before HD
[27] 10 LAL assay(chromogenic)
5.4 pg/dL before HD and 4.63 pg/dL
after HD N/A Before HD and after HD
[8] 66 LAL assay(chromogenic) 0.64 EU/mL ∼0.045 EU/ml (n = 14) Not reported
[28] 59 LAL assay(chromogenic)
0.58 EU/mL (0.51–0.60) and
0.60 EU/mL (0.51–0.63) (before
randomisation to sevelamer
hydrochloride or calcium acetate)
N/A Before HD
[12] 31 LAL assay(chromogenic) 40 ± 4.7 ng/L 7 ± 0.6 ng/L (n = 99) Not reported
[29] 20 LAL assay (gelclot) 0.5 to 5.0 pg/mL in 18 samples N/A
During febrile episodes on
HD
[30] 211 LAL assay(chromogenic) 0.65 (0.43–1.16) EU/mL N/A Before HD
[31] 46 LAL assay(chromogenic)
0.23 ± 0.01 and 0.30 ± 0.01 (patients
taking sevelamer and those not) N/A Before HD
[32] 58
LAL assay
(turbidimetric
kinetic)
0.17 ± 0.11, 0.28 ± 0.15, 0.45 ±
0.16 EU units N/A Before HD and after HD
[33] 17 Laser scatteringphotometry
0.23 EU/mL start of HD and
0.37 EU/mL end of HD N/A During HD
[13] 87 LAL assay(chromogenic)
Significant endotoxaemia detected
in 6/87 HD patients (27.67 ±
23.56 pg/mL)
5.3 ± 1.1 pg/mL (n = 22) During HD
splanchnic ischaemia/hypoxia and resultant lower intestinal
barrier disturbances, this may have subsequent effects on the
concentrations of circulating PC and IS. The investigation
of such an effect is clearly an important future research
direction.
4.3. Intradialytic Exercise. Unlike patients with chronic car-
diac and respiratory diseases, exercise is not a commonly
used therapeutic intervention in HD patients, despite there
being a number of potential benefits [65, 66]. Exercise
interventions that occur during HD sessions (intradialytic
exercise) are being increasingly employed at HD units
[67–69]. However, the potential of intradialytic exercise
to modify the intestinal barrier is yet to be investigated.
Strenuous exercise in the general population has been shown
to disturb the intestinal barrier [34, 59, 70, 71] and results in
elevated levels of circulating endotoxin [35]. During exercise
blood is redistributed towards the exercising muscles and the
skin for heat dissipation and towards tissues with increased
metabolic activity such as the heart, lungs, and brain. This
leads to a subsequent reduction in splanchnic blood flow
[72, 73] and raised core temperature and an increase in ROS
[58, 59, 74], all of which have the ability to disturb the
intestinal barrier and result in the translocation of endotoxin
into the central circulation [38, 59]. Though not specifically
studied, it is likely that these physiological changes will be
amplified during intradialytic exercise [67] as a result of
reductions in blood volume and pressure through the process
of ultrafiltration. In addition, the HDmembrane is known to
increase the production of ROS [75, 76].
In the general population, regular disturbances to the
intestinal barrier during exercise may be advantageous
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through the production of endotoxin antibodies and en-
hanced clearance via the reticuloendothelial system [35],
a form of self-immunisation. Whether regular intradialytic
exercise would have such an effect inHDpatients is uncertain
due to the more persistent change to their intestinal barrier.
There is, however, evidence in HD patients that a six-month
programme of intradialytic exercise reduced the proportion
of monocytes classified as the intermediate subset (CD-
14++CD-16+) [77]. This subset is associated with secretion
of proinflammatory cytokines in response to LPS-stimulation
and a high expression of TLR-4 [78, 79]. Furthermore, ele-
vations in circulating intermediate monocytes are associated
with an increased cardiovascular risk in HD patients [80].
As CD-14 plays a role in endotoxin neutralisation, this may
be a potential mechanism by which circulating endotoxin is
reduced, although clearly further work is needed to corrobo-
rate this.
Intradialytic exercise has previously been shown to
increase aerobic capacity in HD patients [68] and it would
appear that more physically active individuals in the general
population with higher aerobic capacity have lower circu-
lating endotoxin levels [81, 82]. This could contribute to
some of the anti-inflammatory effects associated with regular
physical activity [81]. Whether these data extrapolate to the
HD population remains to be seen but it does seem plausible
that increasing aerobic fitness and physical activity levels
through intradialytic exercise in HD patients might lead to
lower circulating endotoxin concentrations and improved
outcomes.
Regular exercise training programmes in HD patients
may induce favourable changes at a cellular level. Heat Shock
Proteins (HSPs) are intracellular molecular chaperones that
play a role in protein synthesis and cell maintenance [83].
HSPs also have a repair function to enhance cell survival
when challenged by stress and play a regulatory role by
modulating protein transcription activity [84]. Upregulated
HSP levels have been observed following exercise in healthy
individuals [85, 86], and it is increasingly acknowledged that
they play a role in protecting the intestinal barrier against
stress induced changes [57, 59, 87, 88]. Whether this is the
case in HD patients is currently unclear.The strategy of using
nutritional interventions (e.g., glutamine, bovine colostrum,
and zinc carnosine) to directly target the expression of HSP
and protect the intestinal barrier against exercise induced
disturbances has recently proven to be effective [57, 59, 88].
Moreover, there is evidence that probiotic supplementation
may upregulate HSP expression in vitro [89]. Whether these
nutritional therapies could be successfully implemented in
HD patients to modify the microbiota and prevent changes
to the intestinal barrier is unclear, but they certainly have
therapeutic potential and therefore clearly warrant further
attention.
5. Non-Haemodialysis Related Factors
5.1. Uraemia. It has been hypothesised that disturbances
in the intestinal barrier are exacerbated in patients with
ESRD through diffusion of urea into the gut lumen.
Urea is metabolised by gut bacterial urease to ammonia
(CO[NH
2
]2 + H
2
O → CO
2
+ 2NH
3
) which in turn is
hydrolysed to caustic ammonium hydroxide (NH
3
+H
2
O→
NH
4
OH), breaking down the intestinal barrier [90].This was
elegantly shown in two previous studies [91, 92]. T84 cells
were incubated in media containing pre-HD plasma, post-
HD plasma, and plasma from healthy controls [91]. Exposure
of the cells to the pre-HD plasma resulted in a marked
decrease in transepithelial electrical resistance (TER), indi-
cating an increase in permeability [91]. This was paralleled
by reduced expression of the tight junction forming proteins
(claudin and occludin) [91]. Interestingly the intestinal dys-
functionwas significantly less in the cells exposed to the post-
HD, rather than the pre-HD, plasma [91]. It was hypothesised
that it was the presence of unidentified, dialysable product(s)
in uraemic plasma which impaired intestinal barrier func-
tion. In a follow-up study [92], T84 cells were incubated with
clinically relevant concentrations of urea, with the authors
reporting an incremental, concentration dependent fall in
TER and reductions in the expression of claudin, occludin,
and ZO-1. When the T84 cells were incubated with urease to
simulate the microbial environment, reduction in the expres-
sion of tight junction proteins was augmented [92]. These
studies demonstrated that urea is at least partly responsible
for the disturbance to the intestinal barrier, in the absence
of HD induced barrier changes (ischaemia/hypoxia, ROS).
This is also highlighted by other findings [93], which reported
no significant differences in plasma D-lactate (a marker of
intestinal barrier changes) between patients receiving HD
and those choosing conservative treatment [93]. In addition,
McIntyre et al. [8] demonstrated increasing circulating endo-
toxin levels with increasing CKD stage, confirming that the
higher the blood urea concentration, the greater the effect on
the intestinal barrier.
5.2. The Microbiota and Diet. Another important factor that
could disrupt the intestinal barrier in ESRD patients is
changes in the composition of the microbiota. The intestine
is inhabited by some 1014 commensal bacteria which provide
protection against bacterial pathogens by marinating the
intestinal barrier [94]. It is believed that the mechanisms
behind the protective effect of themicrobiota on the intestinal
barrier include stimulating epithelial cell turnover, promot-
ing mucus secretion, upregulation of antimicrobial peptides,
restoring tight junction protein structure, and production
of short-chain fatty acids and bactericidal proteins [94].
Dietary restrictions in ESRD patients significantly alter the
microbiota of the intestinal tract [6]. Restrictions in fruit and
vegetable consumption (sources of potassium) and diets low
in symbiont-rich cheese/yogurt promote a predominance of
bacteria that produce toxic metabolites [50, 95]. These toxic
metabolites, which include the aforementioned PC and IS,
are produced directly from amino acid bacterial fermentation
[49–52]. There is some evidence that dietary interventions
such as high-fibre dietsmay reduce the circulating concentra-
tion of PC and IS [96] and some inflammatory markers [97]
in HD patients. It is thought that this effect is mediated by
the production of short-chain fatty acids, which are used by
the epithelial cells as energy [6]; whether this confers a direct
upregulation of the intestinal barrier is unclear. It is worth
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mentioning that these dietary fibre interventional studies
contain small sample sizes; consequently larger properly
powered investigations with hard end points are necessary.
Finally, orally activated charcoal absorbent has shown to
partially restore expression of some tight junction proteins
and subsequently reduce circulating endotoxin levels in an
animal model [98]. However, perhaps unsurprisingly in two
randomised controlled trials [99, 100] in CKDpatients, orally
activated charcoal absorbent proved ineffective in slowing
CKD progression; these findings suggest it may be ineffi-
cacious in improving outcomes in HD patients. Although
outside the scope of this review per se, these results [99, 100]
highlight the current uncertainty within the literature of the
role that intestinal barrier and microbiota changes have to
play in CKDprogression and outcomes in both CKD andHD
patients.
5.3. Medication. The impact of medication on the intestinal
barrier, circulating endotoxins, and the microbiota in HD
patients is not well understood. It has been postulated that
the frequent use of antibiotics and phosphate binders in
patients with ESRD may alter the microbiota [5, 6] and
consequently compromise the intestinal barrier. Interestingly,
though, a study by Sun et al. [31] showed that patients
taking sevelamer hydrochloride (SH) had lower circulating
endotoxin concentrations, which was followed by another
investigation demonstrating that 3 months of SH ingestion
proved effective in actually lowering circulatory endotoxin
[28]. It has been postulated that SHmay have a direct effect in
the intestinal tract by binding to endotoxins although the pre-
cisemechanism for this effect is yet to be elucidated.Whether
other phosphate binders have similar effects is unclear. Iron
replacement therapy (IRT) is commonly prescribed in HD
patients primarily to increase the efficacy of recombinant ery-
thropoietin therapy [101]; administering iron intravenously
will have secondary effects on the intestinal barrier and
microbiota. There are conflicting results on the effects of
iron administration, with some human and animal studies
reporting increased dysbiosis of the microbiota [102–104];
contrarily, in a randomised controlled trial in inflammatory
bowel disease patients, intravenous IRT resulted in shifts
in microbiota diversity [105] intimating that it may negate
microbiota imbalance.The differences in these results may be
explained by the initial presence or absence of iron deficiency
or anaemia in the studied patients or animals and possibly
the route of administration (oral versus intravenous). IRT
in HD patients may increase microbiota diversity in the
presence of iron deficiency or anaemia; whether this will
have consequences for the intestinal barrier is not known,
although an increased diversity is generally viewed as a
beneficial physiological change.
6. Other Considerations: The
Assessment of Intestinal Barrier Status in
Haemodialysis Patients
The measurement of circulating endotoxin levels has been
the primary method of assessing intestinal barrier status
in HD patients. The Limulus Amoebocyte Lysate (LAL)
assay has been the assay of choice for detecting circulating
endotoxin in this patient population [8, 9, 15, 27] (Table 1).
Endotoxin levels have previously been expressed either in
weight or in endotoxin units (EU) (Table 1); however it has
been recommended that levels should be reported as EU
rather than using weight as a unit of measurement [106].
Consistency of unit reporting will allow study results to be
compared more easily (Table 1).
There is clearly a large variation in previously reported
concentrations of endotoxin in HD patients as can be seen in
Table 1. This variation may be explained by the timing of the
blood samples (either before, during, or after HD), with it not
being clear in some studies when the sample for endotoxin
analysis was obtained in relation to the participants HD
regime [8, 9, 12, 16]. There are a number of substances
contained in uraemic plasma that could interfere with the
detection of endotoxin by the LAL assay [107], and these in
turn could vary throughout the HD process. For example,
beta D-glucan can be introduced to the circulation of patients
through the use of cellulose membranes during HD [108]. It
is possible that the LAL assay may not discriminate between
endotoxin and beta D-glucan [27] resulting in false positive
results, which has been supported by recent data [109].
Concerns relating to differing reporting units and possible
interference of the LAL assay with contaminants (e.g., beta
D-glucan) must be taken into account when interpreting and
comparing data.
Endotoxin can also be introduced exogenously as a
consequence of biofilm formation in the HD machine or in
tunnelled central venous catheters [37, 110], possibly resulting
in an influx of endotoxin during and immediately following
treatment. Additionally, endotoxin may enter the circulation
through contaminated dialysate or water. Taken together, the
potential sources of endotoxin within HD patients are vast
and may not always indicate changes in the integrity of the
intestinal barrier of HD patients.
More recent investigations have employed gut bacterial
DNA fragments as a method to assess intestinal disturbances
in HD patients [10, 93, 111]. When detecting bacterial DNA
it is not always possible to confirm the source (intestinal or
non-intestinal), and so studies cannot always characterise the
bacterial species present in HD patients. Alternate investi-
gations have shown that plasma intestinal-fatty acid binding
protein (I-FABP) is a marker of intestinal “damage” and
associates with intestinal ischaemia [112]. The use of plasma
I-FABP to assess intestinal barrier status in HD patients may
hold promise. However, it is probable that a combination of
these markers may allow a more advanced assessment of the
intestinal barrier status ofHDpatients, as has been previously
suggested [20].
7. Conclusion
The importance of changes to the microbiota as a result
of a number of factors that are unique to HD patients has
received particular recent attention within the literature. The
consequences of modulations to the intestinal barrier and
the microbiota are believed to contribute towards systemic
BioMed Research International 7
Increase Decrease
Urea induced disturbances
The haemodialysis process
(i) Ischaemia/hypoxia 
(ii) Changes in core
temperature
Modifications to
the composition of
diet, medication)
the microbiota (i.e.,
Low ultrafiltration volumes
Nutritional interventions 
(e.g., increased dietary
fibre, probiotics, zinc
carnosine, bovine
colostrum)
Intradialytic exercise?
intestinal barrier
Acute changes to the
(ischaemia-reperfusion, ROS,
etc.)
Cellular adaptations
(increased heat shock protein
expression), anti-inflammatory
effect
Low ultrafiltration rates
Reduce intradialytic
fluid gain
Cooled dialysateGut oedema
Figure 2: Modifications to the intestinal barrier in HD patients.
inflammation in this patient population. Therapeutic inter-
ventions that target the intestinal barrier and the micro-
biota are promising areas of future research in HD pa-
tients.
It is clear that there are a number of factors which are
distinct to HD patients that can disturb the intestinal barrier,
including processes related to, and independent of the HD
process (see Figure 2). Some strategies have been shown to
reduce circulating endotoxin levels in HD patients and in
turn there are nutritional strategies that have been shown to
modify the intestinal barrier. Their efficacy in HD patients is
yet to be shown. It is certainly possible that exercise during
HD may have an anti-inflammatory effect through changes
in circulating endotoxin or on the intestinal barrier directly
(or both), though this is yet to be determined.
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